Effect of Pulmonary Rehabilitation Approaches on Dyspnea, Exercise Capacity, Fatigue, Lung Functions, and Quality of Life in Patients With COVID-19: A Systematic Review and Meta-analysis
Overview
Affiliations
Objective: To qualitatively synthesize and quantitatively evaluate the effect of pulmonary rehabilitation (PR) on dyspnea, lung functions, fatigue, exercise capacity, and quality of life (QoL) in patients with COVID-19.
Data Sources: PubMed, Web of Science, and Cochrane databases were searched from January 2020 to April 2022.
Data Selection: Randomized controlled trials (RCTs) assessing the effect of PR on dyspnea, lung functions, fatigue, exercise capacity, and QoL in patients with COVID-19.
Data Extraction: The mean difference (MD) and a 95% CI were estimated for all the outcome measures using random effect models. The following data were extracted by 2 independent reviewers: (1) first author; (2) publication year; (3) nationality; (4) number of patients included (5) comorbidities; (6) ventilatory support; (7) length of inpatient stay; (8) type of PR; (9) outcome measures; and (10) main findings. The risk of bias was evaluated using the cochrane risk of bias tool.
Data Synthesis: A total of 8 RCTs involving 449 participants were included in the review. PR was found to be significantly effective in improving dyspnea (5 studies, SMD -2.11 [95% CI, -2.96 to -1.27; P<.001]) and exercise capacity (MD 65.85 m [95% CI, 42.86 to 88.83; P<.001]) in patients with both acute and chronic COVID-19 with mild to severe symptoms, whereas fatigue (MD -2.42 [95% CI, -2.72 to -2.11, P<.05]) and lung functions (MD 0.26 L [95% CI, 0.04 to 0.48, P<.05]) were significantly improved in acute COVID-19 patients with mild symptoms. The effect of PR on QoL was inconsistent across studies. PR was found to be safe and feasible for patients with COVID-19.
Conclusion: Evidence from studies indicates that PR program is superior to no intervention in improving dyspnea, exercise capacity, lung functions, and fatigue in patients with COVID-19. PR appears to be safe and beneficial for both acute and chronic COVID-19 patients.
Liu S, Gou B, Zhao Z, Wang Q Arch Rehabil Res Clin Transl. 2025; 6(4):100365.
PMID: 39822207 PMC: 11734016. DOI: 10.1016/j.arrct.2024.100365.
Semphuet T, Jianramas N, Nissapatorn V, Sivakorn C, Pereira M, Ratnarathon A Heliyon. 2024; 10(22):e40453.
PMID: 39634416 PMC: 11615492. DOI: 10.1016/j.heliyon.2024.e40453.
A Narrative Review of Impact of Incentive Spirometer Respiratory Training in Long COVID.
Chen Y, Hsieh Y Int J Gen Med. 2024; 17:5233-5246.
PMID: 39559556 PMC: 11570525. DOI: 10.2147/IJGM.S492772.
Kaddoussi R, Rejeb H, Kalai A, Zaara E, Rouetbi N, Frih Z Biol Sport. 2024; 41(4):197-217.
PMID: 39416495 PMC: 11474993. DOI: 10.5114/biolsport.2024.139072.
Thongchote K, Chinwaro U, Lapmanee S F1000Res. 2024; 11:1284.
PMID: 39281331 PMC: 11393525. DOI: 10.12688/f1000research.126832.2.